groups for each sex. Expected mortality rates were computed by applying the period-, sexand age-specific mortality to the observed person-years in the cohort.
A p-value ≤0.05 (two-sided) was considered statistically significant. Analyses were performed using SPSS 18 and Stata 13. 3, 4 
Definitions and measurements
Time periods were divided in three based on time of HDT-ASCT: 1987 -1995 , 1996 -2002 and 2003 -2008 . Time from HL-diagnosis to HDT-ASCT was dichotomized: more or less than 3 years. Disease status at HDT-ASCT was defined according to standard treatment response criteria after induction chemotherapy: complete remission (CR), complete remission unconfirmed (CRu), partial response (PR) and stable disease (SD). 5 Treatment related mortality was defined as death from a direct complication to HDT-ASCT in tumor free patients, determined from patient charts. Otherwise, the cause of death registered in Statistics
Norway was used as cause of death. Second malignancy (SPM) was defined as any new malignancy other than HL-relapse (non-melanoma skin cancer excluded) diagnosed after HDT-ASCT, until cut-off at December 31th 2011.
